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Abstract Hyperprogressive disease (HPD) has been
recently proposed as a new pattern of progression in
patients treated with immune checkpoint inhibitors (ICIs).
Until now, no biological marker has been found to predict
this accelerated tumour growth. We describe the case of a
62-year-old women who experienced a marked increase in
absolute eosinophil count (AEC) concurrently with a huge
radiological progression after the first nivolumab dose in
absence of other immune-related adverse events (irAEs).
Further investigations are needed to establish the role of
early hypereosinophilia as a marker of progression and to
identify patients who might not benefit from ICI treatment.
Key Points
Hyperprogressive disease (HPD) is a novel pattern of
response during immune checkpoint inhibitor (ICI)
treatment. Immune-related eosinophilia is a
biological immune-related adverse effect with anti-
programmed death 1 (anti-PD-1) or anti-
programmed death ligand 1 (anti-PD-L1).
In this case report, anti-PD-1 administration resulted
in a marked increase in absolute eosinophil count
(AEC) concurrently with a huge radiological
progression.
Early hypereosinophilia may be a negative predictive
factor of ICIs treatment.
Introduction
Anti-programmed death 1 (anti-PD-1) and anti-pro-
grammed death ligand 1 (anti-PD-L1) monoclonal anti-
bodies (mAbs) are immune checkpoint inhibitors (ICIs)
capable of restoring immunity against tumours and
improving survival in several tumour types [1]. Neverthe-
less, some patients seem to not benefit from immunother-
apy and, indeed, it seems that ICIs accelerate the drive
towards progression. In fact, Champiat et al. documented a
new pattern of rapid progression in patients treated with
ICIs: hyperprogressive disease (HPD). It is defined as a
RECIST (Response Evaluation Criteria In Solid Tumors)
progression at the first evaluation and as a C 2-fold
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increase of the tumour growth rate (TGR) between the
reference (prior to treatment onset) and the experimental
(between baseline and the first tumour evaluation) periods
[2]. Kato et al. reported that patients with mouse double
minute 2 homolog (MDM2) family amplifications appear to
be at risk of accelerated progression after immunotherapy
[3]. At present, biomarkers for outcome during immune-
checkpoint blockade are not available and further research
is strongly needed as these may influence individual
treatment choice. Absolute eosinophil count (AEC) has
been recently investigated as a new potential biomarker of
outcome in patients affected by melanoma. An increase in
the eosinophil count has been correlated with an improved
overall survival in metastatic melanoma patients treated
with ipilimumab, and recently it has been studied in
patients during anti-PD-1/anti-PD-L1 treatment [4–8].
Bernard-Tessier et al. proposed immune-related eosino-
philia as a new biological immune-related adverse effect
with anti-PD-1 or anti-PD-L1 [8]. It has been defined as a
clinically significant increase of AEC over 500 per mm3, in
two samples at different times, during anti-PD1 or anti-PD-
L1 treatment. We describe here the first case of a patient
who experienced dramatic hyperprogressive disease and
early elevation of AEC after the first dose of anti-PD-1
treatment.
Case Report
In March 2015, a 60-year-old Caucasian female never
smoker presented to the emergency department with fever
and persistent cough. The chest X-ray and the subsequent
CT scan showed a hilar lung mass on the upper left lobe,
multiple hilar, para-tracheal, subcarinal and prevascular
lymphadenopathies, bone pelvis and vertebral lesions. The
histological examination, obtained by bronchoscopy,
revealed a non-small-cell lung cancer (NSCLC), CK7?
and TTF1? adenocarcinoma, EGFR wt, PD-L1 negative,
ALK and ROS1 not rearranged. She was staged as
cT3N3M1b (stage IV) according to the American Joint
Committee on Cancer Staging Manual, 7th edition [9].
From April 2015 to August 2015, the patient underwent
first-line platinum 75 mg/m2 plus pemetrexed 500 mg/m2
chemotherapy given every 3 weeks for six cycles. The CT
scan performed on August 2015 revealed a complete
response on the lung mass and on lymphadenopathies and a
bone stable disease. The patient continued maintenance
treatment with pemetrexed until July 2016 when the
surveillance CT scan showed an oligoprogression on the
right adrenal gland with a 4-cm mass (SUV 25). In
September 2016, the patient underwent right adrenalec-
tomy (histological examination: NSCLC metastases) and
continued maintenance pemetrexed until November 2016.
The CT scan performed on December 2016 revealed dis-
ease progression on bone metastases, lymphadenopathies
and a recurrence on the adrenalectomy site.
The patient started second-line treatment with docetaxel
75 mg/m2 plus nintedanib 200 mg twice a day every 3
weeks. She experienced AST/ALT grade 2 (G2) elevation
and neutropenia grade 1 (G1). After the third cycle, the CT
scan showed disease progression with new abdominal
lymphadenopathies.
Administration of nivolumab 3 mg/kg every 2 weeks
was started on 29 March 2017 and the patient had a good
clinical status. One week after the first dose, laboratory
tests revealed a marked increase in AEC of 10.7 9 103
(0.0–0.8) and moderate anaemia (Hb 8.4 g/dL). There were
no other perturbations in laboratory tests (blood chemistry
and endocrinological functions). The patient experienced
fatigue (G1), no fever, no rash or any other immune-related
adverse events (irAEs); stool sample was negative for
parasites and heart evaluation was negative for any dam-
age. A thorax CT scan, performed in order to exclude an
eosinophilic pneumonia, revealed a lung recurrence on the
upper left lobe (1.2 9 2 cm). The patient continued clini-
cal observation and received the second nivolumab dose on
12 April 2017. A week later, the patient developed pro-
gressive fatigue and appetite loss; AEC was still increasing
(12.3 9 103). The patient was hospitalized for severe
anaemia and worsening clinical status. A CT scan was
performed on 27 April with evidence of a further increase
of the lung mass on upper left lobe (7.2 9 2.7 cm vs
1.2 9 2 cm), pleural effusion, several liver metastases and
peritoneal carcinomatosis; because of the severe rapidly
progressive anaemia, a gastroscopy was carried out show-
ing multiple neoplastic gastric ulcerative lesions (Fig. 1).
Despite the AEC decreasing (1.1 9 103), nivolumab
treatment was discontinued as a result of clinical deterio-
ration and radiological progression disease. The patient
died 2 months after the last nivolumab dose.
Discussion
Hyperprogressive disease (HPD) has been observed in 9%
of patients treated with anti-PD-1/PD-L1 [2]. It is associ-
ated with older age (C 65 years old) and worse overall
survival. Tumour disease growth acceleration could be
linked to the blockade of PD-1/PD-L1 signalling in com-
bination with genetic cell alterations such as MDM2 family
amplification. Kato et al. identified, among 155 patients
during treatment with ICIs, a time-to-treatment failure
(TTF)\ 2 months in all six patients with MDM2/MDM4
amplification [3]. Moreover, mechanisms of adaptive
resistance and tumour escape such as up-regulation of
alternative immune checkpoints have been observed [10].
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In literature, increase in AEC during treatment with ICIs
has been reported as a favourable biomarker in metastatic
melanoma patients [6, 7]. Recently, Bernard-Tessier et al.
reported the first case series of immune-related
eosinophilia during anti-PD-1/PD-L1 treatment, showing
kinetics leucocyte changes restricted to the eosinophils
lineage [8]. ICIs can lead to interferon (IFN)-c elevation,
which in turn activates JAK-STAT signalling, leading to the
production of interferon-inducible chemokines [11, 12]. In
particular, activation of the STAT1 pathway by IFN-c,
associated with the signalling triggered by tumour necrosis
factor (TNF), is responsible for the induction of IFN-in-
ducible chemokines CXCL9, CXCL10 and CXCL11
attracting TH1 cells [13]. In an animal tumour model study,
authors observed that tumour-infiltrating eosinophils, acti-
vated by TH1 response, secrete chemokines, guiding
CD8? T cells to the tumour, resulting in tumour rejection
and prolonged survival [14]. In addition, IFN-c inhibits
STAT6 signalling, influencing the TH2 response [13, 15].
The presence of an activated TH2 eosinophil response
could sustain M2-like macrophages in tumours and pro-
mote an immunosuppressive and pro-tumour environment
[16]. Hence, the activation and polarization of eosinophil
response could predict tumour growth or tumour rejection.
In our case, the patient experienced dramatic hyper-
progressive disease after the first dose of nivolumab
according to Kato’s criteria, as TTF\ 2 months,[ 50%
increase in tumour burden compared with pre-im-
munotherapy imaging and[ 2-fold increase in progression
pace (Fig. 2). Concurrently, she reported a marked increase
in AEC. At that time, there was no clinical evidence of
allergic manifestation, signs of parasitic infection, or other
irAEs. No other medications were started before or after
the first perfusion of nivolumab. Conversely to literature
findings, we observed a negative association between the
increase in AEC and the outcome.
Conclusions
In summary, this case reports an early eosinophilia after the
first nivolumab infusion, spontaneously recovered. It
occurred simultaneously with clinical deterioration of the
patient and the radiologic finding of hyperprogressive
Fig.1 Endoscopic findings of multiple neoplastic gastric ulcerative
lesions
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Fig.2 Changes in absolute
eosinophil counts during
nivolumab treatment. Arrows
show nivolumab dose
administration
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disease. No other medical conditions could explain the
aetiology of hypereosinophilia and only the time relation
with nivolumab administration may suggest the causality.
We can’t demonstrate the link between the early hypere-
osinophilia and the pattern of hyperprogression. Prospec-
tive studies are needed to determine the precise role of
changes in AEC during treatment with ICIs and to clarify if
the early presentation of hypereosinophilia may be a pre-
dictive factor of ICIs failure and of radiological and clin-
ical hyperprogression.
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